In many types of cancer, receptor tyrosine kinase (RTK) amplification and mutations, PIK3CA mutations and PTEN loss constitutively activate PI3K-AKT-mTOR signaling [35] and thereby reprogram cellular metabolism. This evidence concerns the gene PTEN and cancer.